All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
Introducing
Now you can personalise
your MPN Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Bookmark this article
Bromodomain and extraterminal domain (BET) proteins are transcriptional regulators of oncogenic pathways that drive inflammation in myelofibrosis (MF). CPI-0610 is an oral, selective, small molecule BET inhibitor, that is being studied in Arm 3 of the phase II MANIFEST study (NCT02158858) in combination with ruxolitinib in patients with MF and naïve to JAK inhibitor (JAKi) treatment. The updated safety and efficacy data from this cohort were reported by MPN Hub Steering Committee member John Mascarenhas during the 25th European Hematology Association (EHA) Virtual Congress and are discussed below.1
The MPN Hub’s comprehensive coverage of all three treatment arms of the MANIFEST study can be found here.
The starting dose at Cycle 1 Day 1 and dose regimen for each 21-day cycle were:
Upward titration of either treatment per cycle was allowed if dose titration criteria were met, up to a maximum of:
At the data cut-off, January 9, 2020, 53 patients were treated with the CPI-0610 and ruxolitinib combination. Patient characteristics are outlined in Table 1.
The key patient eligibility criteria included:
Primary endpoints: ≥ 35% spleen volume reduction (SVR35), and ≥ 50% TSS improvement (TSS50) at Week 24.
Secondary endpoints: Assess the safety, pharmacodynamics, alteration in proinflammatory cytokines, and bone marrow fibrosis or morphology.
Table 1. Patient characteristics1
CALR, calreticulin; DIPSS, Dynamic International Prognostic Scoring System; Int-2, Intermediate-2; Hgb, hemoglobin; JAK2, Janus kinase 2; MF, myelofibrosis; MPL, myeloproliferative leukemia virus; TSS, total symptom score *defined as Hgb < 10g/dL |
|
Characteristic |
Arm 3, CPI-0610 + ruxolitinib |
---|---|
Median age, years (range) |
69 (37–85) |
Male gender, n (%) |
39 (73.6) |
DIPSS ≥ Int-2, n (%) |
39 (73.6) |
Primary MF, n (%) |
25 (47.2) |
Anemic,* n (%) |
32 (60.4) |
Median platelet count, (range) |
345 × 109/L (100–1849) |
Median spleen volume, cm3 (range) |
1726.5 (457–7842) |
Median TSS, n (range) |
14 (0–38) |
Mutational status |
|
JAK2, n (%) |
39 (73.6) |
CALR, n (%) |
11 (20.8) |
MPL, n (%) |
2 (3.8) |
High molecular risk, n (%) |
27 (50.9) |
SVR35
A total of 30 patients were evaluable for SVR35 at Week 24. Of these, 14 patients continued to receive the CPI-0610 + ruxolitinib combination for more than 24 weeks, and one patient discontinued before Week 24. SVR35 at Week 24 was reported in 63.3% of patients, with a median change of –52.9% (range, –84.4% to 23.7). The median spleen size was smaller compared to other studies; the baseline spleen size did not have an impact on the degree of spleen size reduction. The baseline platelet count is also lower than in other studies, however, patients with a lower baseline platelet count had at least as meaningful splenic responses as those with higher counts.
TSS50
A total of 29 patients were evaluable for TSS50 at Week 24. TSS50 at Week 24 was observed in 58.6% of patients, with a median change of –64% (range, –100% to 24.2%). Improvements in bone marrow fibrosis by ≥ 1 Grade were reported in 45.5% of patients, following 6 months of CPI-0610 + ruxolitinib treatment. One patient discontinued treatment to undergo bone marrow transplantation following 24 weeks of therapy.
Sixty-four patients were evaluable for safety. Anemia (23.4%; Grade ≥ 3, 15.6%) and thrombocytopenia (13%; Grade ≥ 3, 1.6%) were the most common hematological treatment-emergent adverse events (TEAEs) of any grade. Cytopenias were manageable with dose modifications. The most common non-hematological TEAEs were diarrhea (26.6%), nausea (18.8%), respiratory infection (18.8%), dysgeusia (14.1%,), and fatigue (12.5%). Grade ≥ 3 TEAEs occurred in 3.1% of patients with respiratory infection. Two patients discontinued treatment due to adverse events (infection), which were considered unrelated to CPI-0610 treatment; both patients died.
The results of the Arm 3 cohort from the MANIFEST trial indicate that the combination treatment of CPI-0610 + ruxolitinib was generally well tolerated in patients with MF and naïve to JAKi. The data suggests the combination treatment is potentially synergistic and can enhance efficacy by increasing SVR35 and TSS50 rates at 24 weeks, compared with historical data from previous studies. Additionally, improvements in bone marrow fibrosis were seen along with a lower incidence of Grade ≥ 3 anemia. The improvements seen in hemoglobin with the combination were not previously reported with ruxolitinib alone, which has been shown to aggravate anemia. With these promising results the phase III study is anticipated to start later this year. Earlier results from the MANIFEST study can be found here.
Mascarenhas J, Harrison C, Patriarca A, et al. CPI-0610, a bromodomain and extraterminal domain protein (BET) inhibitor, in combination with ruxolitinib, in JAK inhibitor treatment naïve myelofibrosis patients: update from MANIFEST phase 2 study. Abstract #EP1084. European Hematology Association (EHA) Meeting; Jun 12, 2020; Virtual.
Your opinion matters
Subscribe to get the best content related to MPN delivered to your inbox